MedWatch

Bavarian publishes promising cancer data

Bavarian Nordic has published positive data from a phase II trial with the Danish company’s cancer vaccine CV-301. It lends hope to the possibility of expanding the pipeline.

Foto: Colourbox

New data from a phase II trial with the cancer vaccine CV-301 was published today, and the company behind the vaccine, Denmark-based Bavarian Nordic, calls the results ‘promising’.

In the trial conducted at Duke University, 74 patients who were disease free after surgical resection of metastatic colon cancer received chemotherapy  followed by immunotherapy with CV-30.

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier